shot-button
Ganesh Chaturthi Ganesh Chaturthi
Home > News > India News > Article > WHOs approval for Covaxin likely this month Sources

WHO's approval for Covaxin likely this month: Sources

Updated on: 13 September,2021 12:00 AM IST  |  New Delhi
PTI |

The WHO has so far approved Covid vaccines developed by Pfizer-BioNTech, US pharma majors Johnson & Johnson, Moderna, China's Sinopharm and Oxford-AstraZeneca for emergency use

WHO's approval for Covaxin likely this month: Sources

A vial of Covaxin

The World Health Organization's approval for the indigenous Covid-19 vaccine Covaxin, developed by the Hyderabad-based Bharat Biotech, is likely to come this month, official sources said Monday.


The WHO has so far approved Covid vaccines developed by Pfizer-BioNTech, US pharma majors Johnson & Johnson, Moderna, China's Sinopharm and Oxford-AstraZeneca for emergency use.


Covaxin is one of the six vaccines that have received emergency use authorisation from India's drug regulator and is being used in the nationwide inoculation programme, alongwith Covishield and Sputnik V.


The Centre had told Rajya Sabha in July that all documents required for the WHO's Emergency Use Listing (EUL) have been submitted by Bharat Biotech as of July 9, and the global health body had commenced the review process.

Also read: Covaxin single-dose to Covid-19 infected equivalent to 2 doses for unaffected: ICMR

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!


Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK